Large Cell Neuroendocrine Carcinoma clinical trials

Explore recruiting large cell neuroendocrine carcinoma clinical trials.

Recruiting large cell neuroendocrine carcinoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Large Cell Neuroendocrine Carcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A multicentre phase II, single arm study of Durvalumab (MEDI 4736) with Carboplatin plus Etoposide for 4 cycles followed by Durvalumab maintenance in patients with metastatic pulmonary large-cell neuroendocrine carcinoma (LCNEC) – DUPLE trial

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

DAREON™-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas

Spain, Italy, Portugal, Germany, France, Bulgaria +2 more

Therapeutic exploratory (Phase II) EU CTIS Study details

DAREON™-7: A study to test how well different doses of BI 764532 in addition to chemotherapy are tolerated by people with advanced neuroendocrine cancers

Spain, Belgium, Germany, France, Sweden, Netherlands

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase II, single-arm trial of Atezolizumab/Platinum/Etoposide for the treatment of advanced large-cell neuroendocrine cancer of the lung (LCNEC-ALPINE)

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

FIRST-NEC (GFPC 01-2022) - A multicenter phase II study evaluating the efficacy and safety of the combination of durvalumab with etoposide and platinum as first line treatment in patients with large-cell neuroendocrine carcinomas (LCNECs) of the lung

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Large Cell Neuroendocrine Carcinoma trials by city

Large Cell Neuroendocrine Carcinoma in Toronto Large Cell Neuroendocrine Carcinoma in Vancouver Large Cell Neuroendocrine Carcinoma in Montreal Large Cell Neuroendocrine Carcinoma in Calgary Large Cell Neuroendocrine Carcinoma in Edmonton Large Cell Neuroendocrine Carcinoma in Ottawa Large Cell Neuroendocrine Carcinoma in Winnipeg Large Cell Neuroendocrine Carcinoma in Quebec City Large Cell Neuroendocrine Carcinoma in Hamilton Large Cell Neuroendocrine Carcinoma in Kitchener Large Cell Neuroendocrine Carcinoma in London Large Cell Neuroendocrine Carcinoma in Halifax Large Cell Neuroendocrine Carcinoma in New York Large Cell Neuroendocrine Carcinoma in Los Angeles Large Cell Neuroendocrine Carcinoma in Chicago Large Cell Neuroendocrine Carcinoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease